Literature DB >> 9716932

Neurotransmitter transporters as molecular targets for addictive drugs.

S G Amara1, M S Sonders.   

Abstract

The neurotransmitter dopamine lies at or near the center of current theories of drug abuse and dependence. Multiple lines of evidence indicate that dopaminergic cells play key roles in a variety of motivated behaviors. Accordingly, it is not surprising that cocaine and amphetamines--some of the most widely used illicit drugs--elevate extraneuronal dopamine concentrations through their actions on the plasma membrane dopamine transporter. From the point of view of developing novel pharmacological interventions for the treatment or prevention of psychostimulant abuse, practical benefits may arise from an improved understanding of how neurotransmitter transporters operate and how drugs interact with them.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9716932     DOI: 10.1016/s0376-8716(98)00068-4

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  98 in total

1.  Role of aberrant striatal dopamine D1 receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine.

Authors:  Francesco Napolitano; Alessandra Bonito-Oliva; Mauro Federici; Manolo Carta; Francesco Errico; Salvatore Magara; Giuseppina Martella; Robert Nisticò; Diego Centonze; Antonio Pisani; Howard H Gu; Nicola B Mercuri; Alessandro Usiello
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

2.  Energy landscape of LeuT from molecular simulations.

Authors:  Mert Gur; Elia Zomot; Mary Hongying Cheng; Ivet Bahar
Journal:  J Chem Phys       Date:  2015-12-28       Impact factor: 3.488

3.  Interaction of tyrosine 151 in norepinephrine transporter with the 2β group of cocaine analog RTI-113.

Authors:  Erik R Hill; Xiaoqin Huang; Chang-Guo Zhan; F Ivy Carroll; Howard H Gu
Journal:  Neuropharmacology       Date:  2011-03-21       Impact factor: 5.250

4.  Trimerization of dopamine transporter triggered by AIM-100 binding: Molecular mechanism and effect of mutations.

Authors:  Mary Hongying Cheng; Luca Ponzoni; Tatiana Sorkina; Ji Young Lee; She Zhang; Alexander Sorkin; Ivet Bahar
Journal:  Neuropharmacology       Date:  2019-06-20       Impact factor: 5.250

Review 5.  Appetite suppressants, cardiac valve disease and combination pharmacotherapy.

Authors:  Richard B Rothman; Michael H Baumann
Journal:  Am J Ther       Date:  2009 Jul-Aug       Impact factor: 2.688

6.  Association between polymorphism of the dopamine transporter gene and early smoking onset: an interaction risk on nicotine dependence.

Authors:  Daijun Ling; Tianhua Niu; Yan Feng; Houxun Xing; Xiping Xu
Journal:  J Hum Genet       Date:  2003-12-18       Impact factor: 3.172

7.  A competitive inhibitor traps LeuT in an open-to-out conformation.

Authors:  Satinder K Singh; Chayne L Piscitelli; Atsuko Yamashita; Eric Gouaux
Journal:  Science       Date:  2008-12-12       Impact factor: 47.728

8.  Development of serotonin transporter reuptake inhibition assays using JAR cells.

Authors:  Ann M Decker; Bruce E Blough
Journal:  J Pharmacol Toxicol Methods       Date:  2018-03-16       Impact factor: 1.950

9.  The multiple LIM domain-containing adaptor protein Hic-5 synaptically colocalizes and interacts with the dopamine transporter.

Authors:  Ana M Carneiro; Susan L Ingram; Jean-Martin Beaulieu; Ava Sweeney; Susan G Amara; Sheila M Thomas; Marc G Caron; Gonzalo E Torres
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

10.  Interaction of catechol and non-catechol substrates with externally or internally facing dopamine transporters.

Authors:  Ying-Jian Liang; Juan Zhen; Nianhang Chen; Maarten E A Reith
Journal:  J Neurochem       Date:  2009-03-11       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.